Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center - Top-Institutions - MDSpire

Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center

  • By

  • Alex Ismael Catalán Cabrera

  • Mónica Karem Medina Durand

  • Karen del Rosario Condori Alvino

  • Cesar Augusto Puma Laura

  • Norma Maribel Portilla Marroquin

  • June 1, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Nantes Université – CHU Nantes
    Nantes Université – CHU Nantes

    Nantes, France

    Key Differentiators

    • Pediatric Cardiology
    • Congenital Heart Disease

  • #2

    Royal Brompton Hospital and National Heart & Lung Institute
    Royal Brompton Hospital and National Heart & Lung Institute

    London, United Kingdom

    Key Differentiators

    • Pediatric Cardiology
    • Congenital Heart Disease

  • #3

    Children’s Hospital, University Medical Center Utrecht
    Children’s Hospital, University Medical Center Utrecht

    Utrecht, Netherlands

    Key Differentiators

    • Pediatric Cardiology

  • #4

    Charité–Universitätsmedizin Berlin
    Charité–Universitätsmedizin Berlin

    Berlin, Germany

    Key Differentiators

    • Pediatric Cardiology

  • #5

    Phoenix Children’s
    Phoenix Children’s

    Phoenix, Arizona

    Key Differentiators

    • Pediatric Cardiology

Original Source(s)

Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center

  • by Alex Ismael Catalán Cabrera, Mónica Karem Medina Durand, Karen del Rosario Condori Alvino, Cesar Augusto Puma Laura, Norma Maribel Portilla Marroquin

  • June 1, 2026

Related Content

Celiac Tied to Higher Transplant Rate

Liver transplantation showed the strongest association, although absolute event rates remained low in a nationwide Swedish cohort study.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Troponin Testing and Early MI Discharge

Sixth-generation high-sensitivity cardiac troponin T assay classifies more patients below a low-risk threshold at presentation.